Association between coffee consumption and risk of recurrent venous thromboembolism - Results from the Trøndelag Health Study and Tromsø Study.

Authors

Melliane M Olsen, Sigrid K Brækkan, Kristian Hveem, Kjersti Grønning, John-Bjarne Hansen

Published in

Research and practice in thrombosis and haemostasis. Volume 10. Issue 7. Pages 106966. Epub Sep 15, 2026.

Abstract

Epidemiological studies have shown that coffee consumption is associated with a lowered risk of incident venous thromboembolism (VTE). No previous study has explored whether coffee consumption influences the risk of VTE recurrence.
This study aimed to investigate whether the amount of coffee consumption (cups/d) is associated with the risk of VTE recurrence in a population-based cohort of incident VTEs.
The cohort consisted of 2071 patients with incident VTE recruited from 4 surveys of the Tromsø Study (enrolment, 1994-2008) and the third survey of the Trøndelag Health Study (enrolment, 2006-2008), followed from the date of the index VTE until 2020. Information on coffee consumption (cups/d) and potential confounders was extracted. Cox regression models were used to estimate hazard ratios (HRs) with 95% CIs for VTE recurrence.
During a median follow-up of 2.8 years, 310 recurrent VTEs occurred. There was no linear relationship between increasing coffee intake and VTE recurrence. The HR for recurrence was 0.49 (95% CI, 0.30-0.81) for those consuming 1 to 2 cups of coffee per day and 0.71 (95% CI, 0.44-1.12) for those consuming >6 cups compared with noncoffee consumers. The association between coffee consumption (yes/no) and lowered recurrence risk was more pronounced for provoked index VTE event (HR, 0.50; 95% CI, 0.30-0.82) than for unprovoked index VTE (HR, 1.01; 95% CI, 0.53-1.94).
Coffee consumption was associated with a nonlinear, lowered risk of VTE recurrence, particularly after provoked VTE. Our findings suggest that coffee can be safely consumed after VTE, potentially with a beneficial effect on recurrence risk.

PMID:
42866719
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.